Hypothesis

Age‑related loss of intestinal barrier integrity releases mitochondrial DNA (mtDNA) from gut epithelial cells into the circulation. This gut‑derived mtDNA acts as a damage‑associated molecular pattern (DAMP) that reaches the brain via the vagal afferent pathway, where it engages Toll‑like receptor 9 (TLR9) on microglia and astrocytes, triggering a chronic low‑grade inflammasome activation that establishes the brain’s inflammaging baseline. Consequently, interventions that improve gut barrier function or neutralize circulating mtDNA should attenuate neuroinflammation and extend healthspan, whereas purely neurocentric approaches that ignore intestinal mtDNA flux will have limited efficacy.

Mechanistic Rationale

1. Gut mtDNA efflux – Age‑associated degeneration of the enteric nervous system and loss of interstitial cells of Cajal increase epithelial turnover and barrier permeability, leading to higher plasma cfDNA from colon epithelial and neutrophil sources (p=0.003, p=0.010) [PMC11318736]. A fraction of this cfDNA originates from mitochondria, which are rich in unmethylated CpG motifs characteristic of bacterial DNA and potent TLR9 agonists.
2. Vagal afferent transport – The vagus nerve senses luminal and portal‑vein metabolites; recent work shows it can translocate circulating nucleic acids to the nodose ganglion and subsequently to the nucleus tractus solitarius, providing a direct route for gut‑derived signals to influence central immune cells [PMC10798364].
3. Microglial TLR9 activation – Binding of mtDNA to TLR9 triggers MyD88‑dependent NF‑κB signaling, priming the NLRP3 inflammasome and increasing IL‑1β and IL‑18 production, a cascade linked to neuroinflammation and cognitive decline in aging models [PubMed 37298421].
4. Feedback loop – Brain‑derived sympathetic output can further alter gut motility and permeability, but the primary driver of the inflammatory set‑point is the upstream mtDNA flux, making the axis effectively bottom‑up.

Testable Predictions

• Prediction 1: Old mice with elevated plasma gut‑derived mtDNA will show heightened microglial TLR9 expression and inflammasome markers compared with young controls; pharmacological blockade of TLR9 (e.g., ODN TTAGGG) will reduce these markers without altering gut permeability.
• Prediction 2: Chronic administration of a gut‑barrier‑strengthening agent (e.g., peptidoglycan‑derived muramyl dipeptide or a tight‑junction peptide larazotide) will lower circulating gut mtDNA, decrease brain IL‑1β levels, and improve performance on memory tasks in aged mice.
• Prediction 3: Selective vagotomy (subdiaphragmatic) will abolish the brain‑inflammatory response to elevated gut mtDNA, despite persistent systemic mtDNA elevation, confirming the vagal route as necessary for central signaling.
• Prediction 4: Inverse experiment – direct intracerebroventricular infusion of synthetic gut‑mtDNA mimicking oligonucleotides will recapitulate neuroinflammatory signatures in young animals, demonstrating sufficiency.

Experimental Approach

Use aged (24‑month) C57BL/6 mice. Measure plasma mtDNA by qPCR for mitochondrial‑specific ND1 gene, distinguishing it from nuclear cfDNA. Assess gut barrier integrity via FITC‑dextran permeability. Evaluate microglial activation (Iba1, TLR9, NLRP3, cleaved caspase‑1) and cytokine levels in hippocampus and cortex. Interventions: (a) TLR9 antagonist, (b) barrier enhancer larazotide, (c) subdiaphragmatic vagotomy, (d) ICV mtDNA infusion. Behavioral readouts: Morris water maze and novel object recognition.

Potential Confounds and Controls

Systemic inflammation from other sources (e.g., adipose tissue) could also elevate mtDNA; control by measuring tissue‑specific cfDNA signatures (colon‑epithelial vs. adipocyte‑derived) using methylation markers. Ensure vagotomy does not alter gut permeability independently by monitoring FITC‑dextran post‑surgery.

Implications

If validated, this hypothesis would reposition gut‑derived mtDNA as a proximal driver of brain inflammaging, shifting the longevity intervention stack from neurocentric targets (e.g., anti‑amyloid, HDAC inhibitors) to gut‑centric strategies: barrier reinforcement, mtDNA scavenging (e.g., circulating DNase‑1), or vagal neuromodulation. It also offers a biomarker—plasma gut‑mtDNA level—for predicting neuroinflammatory risk and tracking therapeutic response.